Metastin derivatives and use thereof

Details Metastin derivatives and use thereof Metastin derivatives and use thereof

2005-06-23

2009-12-01

Kosar, Andrew D (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S328000

Reexamination Certificate

active

07625869

ABSTRACT:
The invention provides stable metastin derivatives having excellent biological activities (a cancer metastasis suppressing activity, a cancer growth suppressing activity, etc.). By modifying the constituent amino acids of metastin with specific modifying groups, metastin derivatives having more improved blood stability, etc. than native metastin and showing excellent cancer metastasis suppressing activity or cancer growth suppressing activity have been found. Furthermore, it has been found that these metastin derivatives exhibit effects of suppressing gonadotropic hormone secretion, suppressing sex hormone secretion, etc., which are wholly different from the effects heretofore known.

REFERENCES:
patent: 2003/0096956 (2003-05-01), Suenaga et al.
patent: 2004/0185525 (2004-09-01), Nishimura et al.
patent: 2004/0236077 (2004-11-01), Matsumoto et al.
patent: 2005/0176091 (2005-08-01), Yamada et al.
patent: 2005/0240008 (2005-10-01), Ohtaki et al.
patent: 0162575 (1985-11-01), None
patent: 1 126 028 (2001-08-01), None
patent: 2002320496 (2002-11-01), None
patent: 1 577 323 (2005-09-01), None
patent: 1 577 323 (2005-09-01), None
patent: 1 604 682 (2005-12-01), None
patent: 9-169735 (1997-06-01), None
patent: 2002-320496 (2002-11-01), None
patent: 2003-026601 (2003-01-01), None
patent: 2003300906 (2003-10-01), None
patent: 2004217651 (2004-08-01), None
patent: WO-97/14682 (1997-04-01), None
patent: WO-97/40071 (1997-10-01), None
patent: WO-98/39448 (1998-09-01), None
patent: WO-00/24890 (2000-05-01), None
patent: WO-01/44469 (2001-06-01), None
patent: WO-01/74377 (2001-10-01), None
patent: WO-01/75104 (2001-10-01), None
patent: WO-02/085399 (2002-10-01), None
patent: WO-02/092829 (2002-11-01), None
patent: WO-03/027149 (2003-04-01), None
patent: WO-03/060125 (2003-07-01), None
patent: WO-2004/038021 (2004-05-01), None
patent: WO-2004/060264 (2004-07-01), None
patent: WO-2004/060264 (2004-07-01), None
patent: WO-2004/063221 (2004-07-01), None
patent: WO-2004/080479 (2004-09-01), None
patent: WO-2004/087622 (2004-10-01), None
patent: WO-2004/096855 (2004-11-01), None
patent: WO-2004/101747 (2004-11-01), None
patent: WO-2004/106289 (2004-12-01), None
patent: WO-2005/095973 (2005-10-01), None
patent: WO-2006/001499 (2006-01-01), None
patent: WO-2007/072997 (2007-06-01), None
patent: WO-2007/084211 (2007-07-01), None
Search Report of Corresponding Georgian Patent Application No. 2005 010294, Issue on Dec. 8, 2008.
Official Action of Corresponding Japanese Patent Application No. 2008-245073, Issued on Mar. 31, 2009.
M. Kotani et al., “The Metastasis Suppressor Gene KiSS-1 Encodes Kisspeptins, the Natural Ligands of the Orphan G Protein-coupled Receptor GPR54”,The Journal of Biological Chemistry, vol. 276, pp. 34631-34636 (2001).
M. Ringel et al., “Metastin Receptor is Overexpressed in Papillary Thyroid Cancer and Activates MAP Kinase in Thyroid Cancer Cells”,The Journal of Clinical Endocrinology&Metabolism, 87(5), pp. 2399-2402 (2002).
S. Han et al., “Orphan G Protein-coupled receptors MrgA1 and MrgC11 are Distinctively Activated by RF-amide-related Peptides Through the Gα11 Pathway”,PNAS, vol. 99, No. 23, pp. 14740-14745 (Nov. 12, 2002).
Y. Horikoshi et al., “Dramatic Elevation of Plasma Metastin Concentrations in Human Pregnancy: Metastin as a Novel Plascenta-Derived Hormone in Humans”,The Journal of Clinical endocrinology&Metabolism, 88(2), pp. 914-919 (2003).
Y. Terao et al., “Expression of KiSS-a, a Metastasis Suppressor Gene, in Trophoblast Giant Cells of the Rat Placenta.” Biochimica et Biophysica Acta 1678 (2004) 102-110.
T. Masui et al., “Metastin and its variant forms suppress migration of pancreatic cancer cells.” Biochemical and Biophysical Research Communications 315 (2004) 85-92.
M. L. Gottsch et al., “A Role for Kisspeptins in the Regulation of Gonadotropin Secretion in the Mouse.” Endocrinology 2004 145(9):4073-4077.
T. Ohtaki et al., “Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor.” Nature vol. 411, May 31, 2001 pp. 613-617.
A. Niita et al., “Genome Information Convergent Type of Drug Development Research: Depolymerization of the Cancer Metastasis Suppressor Gene, KiSS-1 (Metastin). 2003 Yuki 2B-13-2.”
A. Dutta et al., “Polypeptides. Part 15 Synthesis and Biological Activity of ∝-Aza-analogues of Luliberin modified in Positions 6 and 10.” Journal of the Chemical Society, Perkin Transactions 1, No. 2, 1979, pp. 379-388.
N. Venkatesan et al., “Synthesis and Enzyme Inhibitory Activities of Novel Peptide Isosteres”,Current Medicinal Chemistry, vol. 9, pp. 2243-2270 (2002).
K. Tomita et al., “Structure—Activity Relationship Study on Small Peptidic GPR54 Agonists”,Bioorganic&Medicinal Chemistry, vol. 14, pp. 7595-7603 (2006).
A. Niida et al., “Design and Synthesis of Downsized Metastin (45-54) Analogs with Maintenance of High GPR54 Agonistic Activity”,Bioorganic&Medicinal Chemistry, vol. 16, pp. 134-137 (2006).
A.I. Muir et al., “AXOR12, a Novel Human G Protein-coupled Receptor, Activated by the Peptide KiSS-1”,The Journal of Biological Chemistry, 276(31), pp. 28969-28975 (2001).

Affiliated with

Also associated with

Rating

Metastin derivatives and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Metastin derivatives and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Metastin derivatives and use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4108095